Research Resource

Creative Biogene is committed to providing high quality products and services to help scientists around the world find solutions in biological research and drug discovery.

Research Areas

Research Progress on Universal Cell Therapy

In order to allow more patients to benefit from immune cell therapy, researchers are now developing safe and effective allogeneic transplant immune cells and preparing universal CAR-immune cells. The successful development of such products will greatly reduce production costs, shorten production time, and better ensure product efficacy, so that more patients can benefit.

Lentiviral Vectors for CAR-T Cell Therapy

As the core link of CAR-T cell therapy, lentiviral packaging technology plays a vital role in the field of tumor immunotherapy. In-depth research on the biological basis and production process of lentiviral packaging and overcoming the current challenges are of far-reaching significance for promoting the development of CAR-T cell therapy technology and even the progress of the entire field of tumor immunotherapy.

VLP Vaccine Guidelines and Comprehensive Analysis of VLP Expression Platforms

As highly structured protein particles, VLPs are conducive to the uptake of antigen-presenting cells and can stimulate the host's innate and adaptive immune response functions. In the past three decades, VLPs have been widely used, especially in the field of vaccines. Some VLP-based vaccines have been used in commercial production or have entered different stages of clinical research.

Kinase Inhibitors And Their Antiviral Potential

The development of corresponding kinase inhibitors to target protein kinases that play a key role in the formation of diseases has become an important means of treating these kinase-related diseases, especially in the field of cancer treatment. Given that phosphorylation regulates many biological processes, protein kinase inhibitors can be used to treat diseases caused by overactive protein kinases or to regulate cell function to overcome other disease drivers.

circRNA: The Emerging Powerhouse of RNA Biology

circRNA is a type of RNA molecule that is a single-stranded closed ring formed by covalent bonds. First, because it lacks free ends, it is not easily degraded by nucleases and has stability. Secondly, the purified engineered circRNA shows low immunogenicity and side effects in vivo, reflecting its safety advantage as a drug. Compared with linear mRNA, circRNA with a closed-loop structure has become an attractive alternative due to its excellent stability, low immunogenicity and sustained expression.

Vaccine Production Processes

Vaccines represent the most economical and effective method for preventing infectious diseases. Modern vaccine technology has evolved beyond traditional pathogen isolation and inactivation to incorporate genetic engineering, immunology, and systems biology. Contemporary production processes include recombinant proteins, virus-like particles, polysaccharide conjugates, viral vectors, inactivated pathogens, DNA vaccines, and mRNA platforms, addressing complex emerging pathogens and expanding therapeutic applications.

Revolutionary Advances in High-Throughput Monoclonal Antibody Screening Technology

A new review in Journal of Biological Engineering highlights groundbreaking advancements in high-throughput monoclonal antibody screening, reducing discovery cycles from months to days. With cutting-edge platforms like phage display, single-cell sequencing, and AI integration, researchers can now achieve rapid, precise antibody development at unprecedented scale.

ADC Process Development and Manufacturing (Part II): Purification Strategies and Production Equipment

This part explores purification strategies and production equipment in ADC manufacturing. It highlights key methods like UF/DF and chromatography for impurity removal and discusses equipment considerations, including single-use vs. reusable systems, to ensure safety, efficiency, and scalability in handling highly potent compounds.

ADC Process Development and Manufacturing (Part I): Core Components, Intermediates, and Conjugation Strategies

This chapter outlines key strategies in ADC development, covering core components, conjugation methods, quality control, and process optimization to ensure the consistent, safe, and effective manufacture of antibody-drug conjugates.

Various AAV Serotypes and their applications in gene therapy

* For research use only. Not intended for any clinical use.

Quick Inquiry